Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase

Francesca Farina, Alessandra Stasia, Carlo Gambacorti-Passerini Department of Health Sciences, University of Milano Bicocca, Monza, Italy Abstract: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of hematological malignancies and solid tumors. ALK con...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Farina F, Stasia A, Gambacorti-Passerini C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/64cb8dcba25d48d38152e7e35cd0adb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:64cb8dcba25d48d38152e7e35cd0adb1
record_format	dspace
spelling	oai:doaj.org-article:64cb8dcba25d48d38152e7e35cd0adb12021-12-02T04:30:14ZDevelopments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase1179-9889https://doaj.org/article/64cb8dcba25d48d38152e7e35cd0adb12014-08-01T00:00:00Zhttp://www.dovepress.com/developments-in-anaplastic-large-cell-lymphoma-targeting-the-anaplasti-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889 Francesca Farina, Alessandra Stasia, Carlo Gambacorti-Passerini Department of Health Sciences, University of Milano Bicocca, Monza, Italy Abstract: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of hematological malignancies and solid tumors. ALK contributes to the development of cancers in different cell lineages through a variety of genetic mechanisms: gene fusions, activating point mutations, and possibly gene amplification. Recent developments led to significant therapeutic advances, including efficient diagnostic tests and ALK-targeting agents. This review addresses some therapeutic considerations with regard to the use of ALK inhibitors in ALK-positive lymphomas where, in spite of the advanced stage of the disease, long-lasting responses could be obtained in a substantial portion of heavily pretreated patients. Data and mechanisms for the development of resistance to ALK inhibitors will also be presented and discussed. Keywords: ALK, lymphoma, tyrosine kinase, targeted therapy, crizotinib Farina FStasia AGambacorti-Passerini CDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 69-79 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Farina F Stasia A Gambacorti-Passerini C Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
description	Francesca Farina, Alessandra Stasia, Carlo Gambacorti-Passerini Department of Health Sciences, University of Milano Bicocca, Monza, Italy Abstract: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of hematological malignancies and solid tumors. ALK contributes to the development of cancers in different cell lineages through a variety of genetic mechanisms: gene fusions, activating point mutations, and possibly gene amplification. Recent developments led to significant therapeutic advances, including efficient diagnostic tests and ALK-targeting agents. This review addresses some therapeutic considerations with regard to the use of ALK inhibitors in ALK-positive lymphomas where, in spite of the advanced stage of the disease, long-lasting responses could be obtained in a substantial portion of heavily pretreated patients. Data and mechanisms for the development of resistance to ALK inhibitors will also be presented and discussed. Keywords: ALK, lymphoma, tyrosine kinase, targeted therapy, crizotinib
format	article
author	Farina F Stasia A Gambacorti-Passerini C
author_facet	Farina F Stasia A Gambacorti-Passerini C
author_sort	Farina F
title	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
title_short	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
title_full	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
title_fullStr	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
title_full_unstemmed	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
title_sort	developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/64cb8dcba25d48d38152e7e35cd0adb1
work_keys_str_mv	AT farinaf developmentsinanaplasticlargecelllymphomatargetingtheanaplasticlymphomakinase AT stasiaa developmentsinanaplasticlargecelllymphomatargetingtheanaplasticlymphomakinase AT gambacortipasserinic developmentsinanaplasticlargecelllymphomatargetingtheanaplasticlymphomakinase
_version_	1718401188246847488

Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase

Ejemplares similares